<DOC>
	<DOCNO>NCT02472665</DOCNO>
	<brief_summary>Multicenter , prospective , non-controlled study pediatric cohort ( &lt; 6 years-old ) severe Von Willebrand Disease ( VWD ) .</brief_summary>
	<brief_title>Efficacy Safety Fanhdi® , High-purity Von Willebrand Containing FVIII Concentrate , Pediatric Patients With Von Willebrand Disease</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Patients diagnose severe hereditary von Willebrand 's disease ( VWF : RCof &lt; 20 IU/dl ) type 1 , 2 3 , independent prior treatment 2 . Patients le 6 year age 3 . Patients adequately respond treatment desmopressin 4 . Positive antiHBs antiHAV antibody due prior exposure vaccination . If negative , vaccination hepatitis A B initiate first infusion Fanhdi® 5 . Signed informed consent patient 's legal representative ( mother , father tutor ) 1 . The subject diagnose acquire VWD 2 . Patients bleed time first infusion 10 day prior infusion 3 . Subjects treat desmopressin another VWF contain FVIII concentrate 5 day prior infusion investigational product 4 . The subject know suspected present past inhibitor activity ( antibody ) direct FVIII VWF 5 . The subject known history intolerance Fanhdi® contain substance 6 . The subject known history anaphylactic reaction ( ) blood blood component 7 . Subjects present severe platelet dysfunction due drug ( aspirin , NSAIDs , etc . ) pathology ( uremic thrombopathy , hematological disease ) 8 . Immunocompromised subject HIV positive less 400 CD4+/microliters , viral load &gt; 400 copies/ml , platelet count lower 100x10e9/l , present additional factor elevate risk bleed life expectancy le 1 year 9 . Subjects present anemia ( hemoglobulin &lt; 11 g/dl ) 10 . Subjects diagnose metabolic disease clinically control , diabetes mellitus , could potentially interfere interpretation study 11 . The subject participate another clinical study involve investigational treatment , participate within past month 12 . If anticipate subject treat product contain FVIII VWF different Fanhdi® period one year 13 . The subject unlikely adhere protocol requirement study 14 . Any subject dispose frozen plasma sample prior first infusion Fanhdi®</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>pediatric</keyword>
	<keyword>plasma-derived FVIII concentrate</keyword>
</DOC>